Skip to content

uniQure QURE Total Non-Current Liabilities

Total Non-Current Liabilities at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$7.59M-37.4%

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's total non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's total non-current liabilities?
uniQure (QURE) reported total non-current liabilities of $570.17M in Q1 2026.
How has uniQure's total non-current liabilities changed year-over-year?
uniQure's total non-current liabilities increased by 6.5% year-over-year, from $535.41M to $570.17M.
What is the long-term trend for uniQure's total non-current liabilities?
Over 5 years (2020 to 2025), uniQure's total non-current liabilities has grown at a 52.1% compound annual growth rate (CAGR), from $69.16M to $563.09M.
What does total non-current liabilities mean?
The sum of all long-term obligations due beyond one year — long-term debt, lease liabilities, pension obligations, and deferred items.